As we approach summer and vacations (at least for some of us in the office and most industry people here in Sweden), we wanted to take a moment to look back at the first half of the year. Here are some highlights of the year so far:
Simsen Diagnostics is announcing a new exciting collaboration with Orion Corporation, a Finnish pharmaceutical company, during a First-in-Human Phase I study to evaluate Orion’s drug candidate, ODM-212.
Simsen Diagnostics announces having received a Vinnova grant through the strategic innovation program Swelife to strengthen Life Science in Sweden and improve public health.
Gothenburg 27th of March – Simsen Diagnostics is excited to announce their selection for Business Sweden’s prestigious Catalyst program, which is a significant step in the company’s journey towards international expansion. The Catalyst program, designed for the most innovative and promising startups in Sweden, aims to provide tailored support to accelerate international growth in chosen markets. Simsen Diagnostics has identified the UK as its target market due to its status as the world’s leading biotech cluster and the presence of a substantial customer base. Simsen Diagnostics is revolutionizing cancer care through its advanced technology for monitoring ctDNA, a biomarker directly correlated with tumor burden. With the help of Simsen Diagnostics’ ultrasensitive tools cancer can be monitored and relapse detected years before standard-of-care tools. The technology can aid in evaluating treatment responses, detecting relapses, and identifying remaining disease. “We’re beyond excited to have been selected for the Catalyst program,” said Camilla Hietanen, Sales
Simsen Diagnostics AB, a leader in cancer monitoring, is pleased to announce a collaboration with Professor Peter Naredi and his research group at Sahlgrenska University Hospital. This partnership focuses on enhancing the detection and monitoring of pancreatic cancer, using Simsen Diagnostics’ technology, Simsen Personal. Pancreatic cancer is one of the most deadly cancers, often diagnosed at an advanced stage. Early detection is challenging due to the limited sensitivity of current diagnostic tools. To overcome these obstacles, Naredi and his research group aim to investigate Simsen Diagnostics’ solution, Simsen Personal—a highly sensitive method for detecting and monitoring cancer DNA from blood samples. The collaboration seeks to utilize Simsen Personal aiming to identify the disease in its early stages. Professor Peter Naredi, leading the research group at the Department of Surgery, Sahlgrenska University Hospital, stresses the importance of early detection. “The only chance for a cure is to detect tumors in the
Göteborg, 2024-01-19 – Simsen Diagnostics, a pioneer in cancer monitoring solutions, today announced that Gustav Johansson will be stepping down from his role as CEO from April 1, 2024. Under his leadership, Simsen Diagnostics has successfully transitioned from an academic concept to a commercially viable enterprise, now ready to enter its next phase of growth. “Gustav has been the driving force behind Simsen Diagnostics’ journey from an academic spin-out to a leader in the cancer diagnostics industry. His dedication to innovation and patient care has set a solid foundation for the company,” said Anders Waas, chairman of the board of Simsen Diagnostics. “As we look to the future, we are excited to find a new leader who can build on this legacy and lead us through the next phase of growth and beyond.” Gustav’s decision to step down aligns with the company’s strategic plan to scale operations and expand its
Pontus Rehn has over 20 years of experience in commercial leadership roles in the medical device and IVD industries, including global and regional positions like VP Market Development, Chief Commercial Officer, and Director of Commercial Strategy.
Lina Said, a licensed Biomedical Scientist, brings 18 years of experience from Sahlgrenska University Hospital to her role as the Lab and Quality Manager at Simsen Diagnostics. Her primary focus is ensuring quality assurance and fostering an optimal work environment for the lab.
My Vu is currently doing a master’s degree in biotechnology and demonstrates expertise in laboratory procedures. Her previous experience includes analyzing COVID samples and conducting her bachelor’s thesis at Fraunhofer. My is analyzing all the samples that comes to the lab.
Stefan Filges, an accomplished bioinformatician with a Ph.D. in ultrasensitive sequencing, became part of Simsen Diagnostics in 2022. He played a crucial role as a co-author in the original publication of SiMSen-Seq, which was published in Nature Protocols.
Camilla Hietanen holds an M.Sc. in Business Development from the Chalmers School of Entrepreneurship. Her academic background encompasses studies in Sports & Nutrition, and she brings prior experience from various Start-ups. Within Simsen Diagnostics, her primary focus lies in Sales and Marketing.
Sign up on our maillist to gain access to your article. You can at any time unsubscribe from the list.